← Browse by Condition
Medical Condition
advanced solid tumor
Total Trials
40
Recruiting Now
40
Trial Phases
Phase 1, Phase 2, Phase 1, Phase 2
NCT06533059 Phase 1
Recruiting
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
Enrollment
110 pts
Location
United States, Austr...
Sponsor
Alterome Therapeutics, Inc.
NCT07269080 Phase 1
Recruiting
STM-06: POLARIS-POlymetastic Lesion Ablative Radiotherapy With Immunotherapy Study
Enrollment
28 pts
Location
United States
Sponsor
University of Illinois at Chic...
NCT03767075 Phase 2
Recruiting
A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)
Enrollment
1,000 pts
Location
France, Germany, Ita...
Sponsor
Vall d'Hebron Institute of Onc...
NCT06163391 Phase 1
Recruiting
A Study to Assess Safety and Efficacy of SOT201 in Patients With Advanced/Metastatic Cancer
Enrollment
40 pts
Location
United States, Belgi...
Sponsor
SOTIO Biotech AG
NCT07284186 Phase 1
Recruiting
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Enrollment
155 pts
Location
United States
Sponsor
Plexium, Inc.
NCT07260591 Phase 1
Recruiting
VSV-02 Compassionate Use in Advanced Solid Tumors
Enrollment
6 pts
Location
China
Sponsor
The First Affiliated Hospital ...
NCT05983523 Phase 1
Recruiting
A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients with Advanced or Metastatic Solid Tumors
Enrollment
54 pts
Location
Taiwan
Sponsor
PharmaEngine
NCT06233942 Phase 1
Recruiting
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors
Enrollment
308 pts
Location
United States, Austr...
Sponsor
BeOne Medicines
NCT06997029 Phase 1
Recruiting
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
Enrollment
234 pts
Location
United States, Denma...
Sponsor
Bristol-Myers Squibb
NCT06139211 Phase 1, Phase 2
Recruiting
A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors
Enrollment
186 pts
Location
China
Sponsor
Shanghai Junshi Bioscience Co....
NCT06587295 Phase 1
Recruiting
Intramuscular ACM-CpG Monotherapy in Patients With Advanced/Metastatic Solid Tumors With Prior Response to Immunotherapy Alone or in Combination With Chemotherapy
Enrollment
40 pts
Location
Singapore
Sponsor
National Cancer Centre, Singap...
NCT06130254 Phase 1
Recruiting
Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers
Enrollment
52 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
NCT06251310 Phase 1
Recruiting
SW-682 in Advanced Solid Tumors
Enrollment
186 pts
Location
United States
Sponsor
SpringWorks Therapeutics, Inc.
NCT06938880 Phase 1, Phase 2
Recruiting
Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors
Enrollment
60 pts
Location
China
Sponsor
Suzhou Zelgen Biopharmaceutica...
NCT04390737 Phase 1, Phase 2
Recruiting
Evaluate the Safety and Clinical Activity of HH2853
Enrollment
254 pts
Location
United States, China
Sponsor
Haihe Biopharma Co., Ltd.
NCT04510766
Recruiting
Tumor Molecular Profiling in Early Phase Clinical Trials
Enrollment
40 pts
Location
Switzerland
Sponsor
Oncology Institute of Southern...
NCT05768932 Phase 1
Recruiting
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
Enrollment
260 pts
Location
United States, South...
Sponsor
SillaJen, Inc.
NCT06408688 Phase 4
Recruiting
Safety and Modulation of Adaptive Immunity by Iscador® Qu Viscum Album Extract in Patients With Advanced, Recurrent or Metastatic Cancers Treated With Immune Checkpoint Inhibitors
Enrollment
100 pts
Location
Switzerland
Sponsor
University Hospital, Basel, Sw...
NCT06247657 Phase 1
Recruiting
A Phase I Study to Assess the Safety and Tolerability of BL0006 for Patients With Advanced Solid Tumours
Enrollment
66 pts
Location
China
Sponsor
Shanghai Best-Link Bioscience,...
NCT06682780 Phase 1, Phase 2
Recruiting
A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours
Enrollment
320 pts
Location
China
Sponsor
LaNova Medicines Limited
NCT07083323 Phase 1, Phase 2
Recruiting
A Phase I/II Study of HY05350 in Mesothelin(MSLN)-Positive Advanced Solid Tumors
Enrollment
262 pts
Location
China
Sponsor
Sichuan Huiyu Pharmaceutical C...
NCT05875168 Phase 1, Phase 2
Recruiting
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
Enrollment
540 pts
Location
United States, Belgi...
Sponsor
Daiichi Sankyo
NCT06887348
Recruiting
A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3
Enrollment
50 pts
Location
United States, Austr...
Sponsor
Replimune Inc.
NCT05038150 Phase 1, Phase 2
Recruiting
Study of SGN1 in Patients With Advanced Solid Tumor
Enrollment
70 pts
Location
United States, China
Sponsor
Guangzhou Sinogen Pharmaceutic...
NCT06132503 Phase 1
Recruiting
Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors
Enrollment
110 pts
Location
United States
Sponsor
Lantern Pharma Inc.
NCT05329103 Phase 1
Recruiting
A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors
Enrollment
65 pts
Location
United States
Sponsor
Peel Therapeutics Inc
NCT05661461 Phase 1
Recruiting
Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment
Enrollment
28 pts
Location
United States
Sponsor
Aadi Bioscience, Inc.
NCT06660654 Phase 2
Recruiting
A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)
Enrollment
200 pts
Location
United States, Belgi...
Sponsor
Daiichi Sankyo
NCT06577194 Phase 2
Recruiting
A Single-Center, Single-Arm Study of Neoadjuvant Short-Course Radiotherapy With IL-2 Followed by Sequential Immunotherapy With CAPOX Combined With PD-1 Antibody and IL-2 for Locally Advanced Rectal Cancer
Enrollment
35 pts
Location
China
Sponsor
The First Affiliated Hospital ...
NCT06173219 Phase 1, Phase 2
Recruiting
Safety and Efficacy of Radiotherapy Combined with Immunotherapy for Advanced Malignant Tumors.
Enrollment
38 pts
Location
China
Sponsor
China-Japan Friendship Hospita...
NCT06170294 Phase 1
Recruiting
MAGE-A4-directed TCR-T in the Treatment Amongst Subjects With Advanced Solid Tumors
Enrollment
20 pts
Location
China
Sponsor
Peking University
NCT05819684 Phase 1
Recruiting
A Study of SHR-4602 in Subjects With Advanced Malignant Solid Tumors
Enrollment
133 pts
Location
China
Sponsor
Suzhou Suncadia Biopharmaceuti...
NCT06973863 Phase 1
Recruiting
A Study of PEP08 in Patients With MTAP-Del Advanced or Metastatic Solid Tumors
Enrollment
40 pts
Location
Australia, Taiwan
Sponsor
PharmaEngine
NCT06258408 Phase 1
Recruiting
A Phase 1 Study of BB102 in Participants With Advanced Solid Tumors
Enrollment
78 pts
Location
China
Sponsor
Broadenbio Ltd., Co.
NCT06463340 Phase 1
Recruiting
Study of SGR-3515 In Participants With Advanced Solid Tumors.
Enrollment
52 pts
Location
United States, Canad...
Sponsor
Schrödinger, Inc.
NCT04585750 Phase 1, Phase 2
Recruiting
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Enrollment
300 pts
Location
United States, Austr...
Sponsor
PMV Pharmaceuticals, Inc
NCT05873686 Phase 1
Recruiting
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
Enrollment
140 pts
Location
United States, Unite...
Sponsor
Nuvectis Pharma, Inc.
NCT05269316 Phase 1, Phase 2
Recruiting
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
Enrollment
61 pts
Location
United States, Austr...
Sponsor
Impact Therapeutics, Inc.
NCT06154291 Phase 1, Phase 2
Recruiting
FIH XON7 in Advanced/Metastatic Solid Tumors
Enrollment
255 pts
Location
Belgium, France
Sponsor
Xenothera SAS
NCT04890613 Phase 1
Recruiting
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
Enrollment
52 pts
Location
United States, Canad...
Sponsor
Senhwa Biosciences, Inc.